Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients

• Min Ding ,

  Contributed equally to this work with: Min Ding, Ying Wang

  Affiliation Department of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

  ⨯
• Ying Wang ,

  Contributed equally to this work with: Min Ding, Ying Wang

  Affiliation Laboratory of Gene and Viral Therapy, Eastern Hepatobiliary Surgery Hospital, the Second Military Medical University of Chinese PLA, Shanghai, China

  ⨯
• Jiachang Chi,

  Affiliation Department of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

  ⨯
• Tao Wang,

  Affiliation Department of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

  ⨯
• Xiaoyin Tang,

  Affiliation Department of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

  ⨯
• Dan Cui,

  Affiliation Department of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

  ⨯
• Qijun Qian,

  Affiliation Laboratory of Gene and Viral Therapy, Eastern Hepatobiliary Surgery Hospital, the Second Military Medical University of Chinese PLA, Shanghai, China

  ⨯
• Bo Zhai

  * E-mail: zhaiboshi@sina.com

  Affiliation Department of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

  ⨯